Drug Profile
Research programme: type 2 diabetes therapeutics - Southeast TechInventures
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Southeast TechInventures
- Class
- Mechanism of Action Peroxisome proliferator-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Metabolic syndrome; Type 2 diabetes mellitus
Highest Development Phases
- No development reported Metabolic syndrome; Type 2 diabetes mellitus
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Metabolic-syndrome in USA
- 28 Sep 2020 No recent reports of development identified for research development in Type-2-diabetes-mellitus in USA
- 11 Aug 2016 Research programme: type 2 diabetes therapeutics - Southeast TechInventures is available for licensing as of 11 Aug 2016. http://www.setechinv.com/index.php